Publications
Scientific articles published by the researchers of Barcelonaβeta Brain Research Center (BBRC), related to Alzheimer's disease, neuroimaging, memory and neurodegenerative diseases, among other fields.
-
Buongiorno M, Sánchez-Benavides G, Marzal-Espí C, Giraldo DM, Krupinski J, Cullell N, Grau-Rivera O, Suárez-Calvet M, Gispert JD, de la Sierra A
Alzheimer's Disease Neuroimaging Initiative. Blood-brain barrier permeable β-blockers association with Alzheimer's disease cerebrospinal fluid biomarkers levels in non-demented individuals
Journal of Alzheimer's DiseaseAbstractβ-blockers that easily cross the blood-brain barrier (BBB) seem to diminish the risk of Alzheimer's disease (AD), hypothetically facilitating waste clearance. However, their effect on AD...
-
Zeng H, Schagen SB, Hendriks LEL, Sánchez-Benavides G, Jaspers JPM, Manero RM, Lievens Y, Murcia-Mejía M, Kuenen M, Rico-Oses M, Albers EAC, Samper P, Houben R, de Ruiter MB, Dieleman EMT, López-Guerra JL, De Jaeger K, Couñago F, Lambrecht M, Calvo-Crespo P, Belderbos JSA, De Ruysscher DKM, Rodríguez de Dios N.
Impact of HA-PCI on self-reported cognitive functioning and brain metastases in small-cell lung cancer: Pooled findings of NCT01780675 and PREMER trials
Lung CancerAbstractBackground: Cognitive decline is an arising concern in patients who need cranial irradiation. We used the pooled longitudinal individual patient data of two phase III trials: NCT01780675 and PREMER to...
-
Collij LE, Bollack A, La Joie R, Shekari M, Bullich S, Roé-Vellvé N, Koglin N, Jovalekic A, Garciá DV, Drzezga A, Garibotto V, Stephens AW, Battle M, Buckley C, Barkhof F, Farrar G, Gispert JD
Centiloid recommendations for clinical context-of-use from the AMYPAD consortium
Alzheimer's DementiaAbstractAmyloid-PET quantification through the tracer-independent Centiloid (CL) scale has emerged as an essential tool for the accurate measurement of amyloid-β (Aβ) pathology in Alzheimer's disease (AD)...
-
Collij LE, Bischof GN, Altomare D, Bader I, Battle M, Vállez García D, Lopes Alves I, Wolz R, Gismondi R, Stephens A, Walker Z, Scheltens P, Nordberg A, Gispert JD, Drzezga A, Perissinotti A, Morbelli S, Buckley C, Garibotto V, Frisoni GB, Farrar G, Barkhof F;
Quantification Supports Amyloid PET Visual Assessment of Challenging Cases: Results from the AMYPAD Diagnostic and Patient Management Study
Journal of Nuclear MedicineAbstractSeveral studies have demonstrated strong agreement between routine clinical visual assessment and quantification, suggesting that quantification approaches could support assessment by less experienced...
-
Simrén J, Ashton NJ, Suárez-Calvet M, Zetterberg H
Alzheimer's disease-Biomarkers, clinical evaluation or both?
Journal of Neuropsychology -
Del Campo M, Quesada C, Vermunt L, Peeters CFW, Hok-A-Hin YS, Trieu C, Braber AD, Verberk IMW, Visser PJ, Tijms BM, van der Flier WM, Teunissen CE
CSF proteins of inflammation, proteolysis and lipid transport define preclinical AD and progression to AD dementia in cognitively unimpaired individuals
Molecular NeurodegenerationAbstractThis preclinical AD CSF proteome study identified a panel of 12-CSF markers detecting amyloid positivity and clinical progression to AD with high accuracy; some of these CSF proteins related to immune...
-
Western D, Timsina J, Wang L, Wang C, Yang C, Phillips B, Wang Y, Liu M, Ali M, Beric A, Gorijala P, Kohlfeld P, Budde J, Levey AI, Morris JC, Perrin RJ, Ruiz A, Marquié M, Boada M, de Rojas I, Rutledge J, Oh H, Wilson EN, Le Guen Y, Reus LM, Tijms B, Visser PJ, van der Lee SJ, Pijnenburg YAL, Teunissen CE, Del Campo Milan M, Alvarez I, Aguilar M; Dominantly Inherited Alzheimer Network (DIAN); Alzheimer’s Disease Neuroimaging Initiative (ADNI); Greicius MD, Pastor P, Pulford DJ, Ibanez L, Wyss-Coray T, Sung YJ, Cruchaga C
Proteogenomic analysis of human cerebrospinal fluid identifies neurologically relevant regulation and implicates causal proteins for Alzheimer's disease
Nature GeneticsAbstractThe integration of quantitative trait loci (QTLs) with disease genome-wide association studies (GWASs) has proven successful in prioritizing candidate genes at disease-associated loci. QTL mapping has...
-
Pelkmans W, Gispert JD.
Astroglial reactivity is a key modulator of Alzheimer's disease pathological progression
Brain: a journal of neurologyAbstractThis scientific commentary refers to ‘Association of glial fibrillary acid protein, Alzheimer's disease pathology and cognitive decline’ by Peretti et al. (https://doi.org/10.1093/brain/awae211).
-
Medaglia S, Reig-Palou J, Bellés A, Moreno-Ruiz N, Rodríguez J, Armengol X, Aróstegui JI, Armengol L, Guillén JJ, Laayouni H, Casals F
The Excess of Carriers in Rare Disorders Suggests a Nonpathogenic Effect for Most Variants of Uncertain Significance
Clinical GeneticsAbstractFunctional annotation and interpretation of genetic variants are a critical step in genetic diagnosis, as it may lead to personalized therapeutic options and genetic counseling. While the number of...
-
Therriault J, Janelidze S, Benedet AL, Ashton NJ, Arranz Martínez J, Gonzalez-Escalante A, Bellaver B, Alcolea D, Vrillon A, Karim H, Mielke MM, Hyung Hong C, Roh HW, Contador J, Puig Pijoan A, Algeciras-Schimnich A, Vemuri P, Graff-Radford J, Lowe VJ, Karikari TK, Jonaitis E, Brum W, Tissot C, Servaes S, Rahmouni N, Macedo AC, Stevenson J, Fernandez-Arias J, Wang YT, Woo MS, Friese MA, Jia WL, Dumurgier J, Hourregue C, Cognat E, Ferreira PL, Vitali P, Johnson S, Pascoal TA, Gauthier S, Lleó A, Paquet C, Petersen RC, Salmon D, Mattsson-Carlgren N, Palmqvist S, Stomrud E, Galasko D, Son SJ, Zetterberg H, Fortea J, Suárez-Calvet M, Jack CR Jr, Blennow K, Hansson O, Rosa-Neto P.
Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability
Nature AgingAbstractRecently approved anti-amyloid immunotherapies for Alzheimer's disease (AD) require evidence of amyloid-β pathology from positron emission tomography (PET) or cerebrospinal fluid (CSF) before...
